CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
细胞因子释放综合征被确定为与 CAR-T 后低白蛋白血症相关的显著风险因素。
本研究评估嵌合抗原受体(CAR)T细胞治疗不同阶段患者的营养状态,并识别CAR-T 治疗后低白蛋白血症的主要危险因素。既往临床研究证据日益凸显营养不良对癌症患者的临床影响。考虑到CAR-T 疗法治疗强度高且可能产生副作用,应为患者营养健康提供充分医疗关注与支持。
本研究于2021年5月至12月在浙江大学医学院附属第一医院骨髓移植中心开展,纳入接受CAR-T 治疗的患者。采用Logistic回归分析低白蛋白血症相关危险因素。参与者分为细胞因子释放综合征(CRS)组(n=60)和非CRS组(n=11),进一步分析低白蛋白血症与CRS的关系。
CRS(OR=13.618;95%置信区间1.499–123.709;P=0.013)和基线白蛋白(ALB)水平(OR=0.854;95%置信区间0.754–0.967;P=0.020)是CAR-T 后低白蛋白血症的独立临床相关因素。按血清白蛋白最低值分析,重度CRS患者低白蛋白血症最常见(78.57%)。血清白蛋白最低值(r=−0.587,P<0.001)及出院时血清白蛋白(r=−0.315,P=0.01)与CRS持续时间呈负相关。此外,低白蛋白血症患者住院时间更长(P=0.04)。
CRS是CAR-T 治疗后低白蛋白血症的重要危险因素。随着CRS分级升高、持续时间延长,血清白蛋白明显下降;但仍需进一步研究阐明CRS相关低白蛋白血症的机制。
This study was conducted from May 2021 to December 2021 among patients undergoing CAR-T cell therapy at the Bone Marrow Transplantation Center in The First Affiliated Hospital of Zhejiang University School of Medicine. Logistic regression analysis was performed to investigate the risk factors associated with hypoalbuminemia. Participants were divided into the cytokine release syndrome (CRS) group (n = 60) and the non-CRS group (n = 11) to further analyze the relationship between hypoalbuminemia and CRS.
CRS (OR = 13.618; 95% CI = 1.499-123.709; P = 0.013) and baseline albumin (ALB) (OR = 0.854; 95% CI = 0.754-0.967; P = 0.020) were identified as the independent clinical factors associated with post-CAR-T hypoalbuminemia. According to the nadir of serum albumin, hypoalbuminemia occurred most frequently in patients with severe CRS (78.57%). The nadir of serum albumin (r = - 0.587, P < 0.001) and serum albumin at discharge (r = - 0.315, P = 0.01) were negatively correlated for the duration of CRS. Furthermore, patients with hypoalbuminemia deserved longer hospitalization (P = 0.04).
CRS was identified as a significant risk factor associated with post-CAR-T hypoalbuminemia. An obvious decline in serum albumin was observed as the grade and duration of CRS increase. However, further research is still needed to elucidate the mechanisms of CRS-associated hypoalbuminemia.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。